This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Chesterbrook, PA-based AmerisourceBergen is one of the world’s largest pharmaceutical services companies, which focuses on providing drug distribution and related services to reduce health care costs and improve patient outcomes. The company reports through two segments – Pharmaceutical Distribution and Other. The Pharmaceutical Distribution business includes the operations of AmerisourceBergen Drug Corporation (ABDC) and AmerisourceBergen Specialty Group (ABSG). The segment services healthcare providers in the pharmaceutical supply channel. The ABSG division provides pharmaceutical distribution and other services mainly to physicians, who specialize in a variety of diseases, especially oncology, and to other health care providers, including dialysis clinics. The ABDC division is involved in the distribution of branded pharma drugs and generic drugs, over-the-counter healthcare products, home healthcare supplies and equipment and related services to a range of healthcare providers.
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Should SPDR Russell 1000 Low Volatility Focus ETF (ONEV) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for ONEV
Is SPDR Russell 1000 Low Volatility Focus ETF (ONEV) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for ONEV
AmerisourceBergen (ABC) Beats on Q3 Earnings, Ups '23 EPS View
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter 2023 results benefit from segmental growth. Inflation and unfavorable currency rates hurt operating margin.
AmerisourceBergen (ABC) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
Although the revenue and EPS for AmerisourceBergen (ABC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AmerisourceBergen (ABC) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
AmerisourceBergen (ABC) delivered earnings and revenue surprises of 3.18% and 5.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Improvement in U.S. dialysis treatments per day and cost-saving initiatives are likely to have boosted DaVita's (DVA) second quarter's top line.
Is a Beat Likely for DENTSPLY SIRONA (XRAY) in Q2 Earnings?
by Zacks Equity Research
DENTSPLY SIRONA's (XRAY) second-quarter 2023 results are likely to reflect recovery in demand for consumable products, partially offset by lower sales in China due to volume-based procurement policy.
Is a Surprise Coming for AmerisourceBergen (ABC) This Earnings Season?
by Zacks Equity Research
AmerisourceBergen (ABC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Revvity (RVTY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Revvity's (RVTY) second-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
McKesson (MCK) to Report Q1 Earnings: Is a Beat in Store?
by Zacks Equity Research
McKesson's (MCK) fiscal first-quarter 2024 results are likely to reflect the solid display by the U.S. Pharmaceutical and Specialty Solutions segment.
BD (BDX) Gears Up for Q3 Earnings: What's in the Offing?
by Zacks Equity Research
Continued strength in BD's (BDX) Life Sciences segment's base business is expected to have benefited Q3 sales.
CVS Health (CVS) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
We expect brand price inflation, new product launch, higher utilization and new PBM clients to have contributed to second-quarter growth for CVS Health (CVS).
Henry Schein (HSIC) Set to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Henry Schein's (HSIC) second-quarter 2023 results are likely to be aided by the Dental business and new buyouts.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
Lantheus (LNTH) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Lantheus' (LNTH) second-quarter results are likely to reflect solid top-line performance on the back of robust product adoption.
AmerisourceBergen (ABC) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
AmerisourceBergen (ABC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for AmerisourceBergen (ABC) in Q3 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal third-quarter 2023 results are likely to reflect solid performance at the U.S. Healthcare Solutions segment.
Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?
by Zacks Equity Research
Bio-Rad Laboratories' (BIO) second-quarter 2023 results are likely to reflect an impressive performance across its Clinical Diagnostics business.
BD (BDX) Receives FDA Nod to Address Critical Infusion Needs
by Zacks Equity Research
The latest regulatory clearance for BD's (BDX) Alaris Infusion System is expected to improve healthcare system efficiency via better care coordination and utilization of actionable information.
Reasons to Add HealthEquity (HQY) Stock to Your Portfolio
by Zacks Equity Research
HealthEquity's (HQY) strength in HSA raises optimism about the stock.
STERIS (STE) Set to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
STERIS' (STE) first-quarter fiscal 2024 results are likely to reflect an impressive performance across the Healthcare and AST segments.
Take the Zacks Approach to Beat the Market: NVIDIA, Oracle, Celsius in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
GE HealthCare (GEHC) to Report Q2 Earnings: What's in Store?
by Zacks Equity Research
GE HealthCare's (GEHC) Imaging revenue growth in Q2 is expected to have been led by Magnetic Resonance as well as its molecular imaging entity.